Source: Cancer Network , June 2025
Adoption of Newer Immunotherapy Regimens
Key Discussion Points:
- Community adoption of newer immunotherapy combinations
- Evidence-based decision-making in regimen selection
- Factors influencing uptake of nivolumab/relatlimab in clinical practice
Key Points for Physicians:
- Long-term efficacy data from CheckMate 067 continues to influence treatment selection, though growing confidence in nivolumab/relatlimab is emerging with longer follow-up
Practical advantages of nivolumab/relatlimab include its 30-minute infusion every 4 weeks schedule and improved toxicity profile.